The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to
increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian
community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a
clinical research study seeking to determine whether removing barriers (cost, insurance,
specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the
treatment of HCV will impact health in Perry County, Kentucky.
Phase:
Phase 4
Details
Lead Sponsor:
Jennifer Havens
Collaborators:
Gilead Sciences Icahn School of Medicine at Mount Sinai National Cancer Institute (NCI) National Institute on Drug Abuse (NIDA) University of Bristol University of Kentucky
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir